Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-07-12
2004-04-06
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S036000, C514S037000, C514S038000, C514S039000, C514S040000, C514S152000, C514S254080
Reexamination Certificate
active
06716822
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a therapeutic agent for ischemia, more specifically, to a therapeutic agent for ischemia which inhibits apoptosis under ischemic condition.
2. Description of the Prior Art
As the death rate from cardiovascular diseases is increasing recently, researches on the cardiovascular diseases are now in rapid progress. Among them, one of the most noticeable field is that relating to thrombus, wherein efforts to restore blood vessel functions by dissolving thrombus which is the major cause of blockage of blood vessels, and, furthermore, to inhibit thrombus formation are being made. However, there is little progress in developing method for preventing ripple effects of blockage of blood vessels caused by thrombus or other causes. Accordingly, in case of a patient dying of the blockage of blood vessels, it is almost impossible to alleviate ischemic injury which lacks an adequate supply of oxygen and glucose.
It has been reported that administration of antibiotics to the patient who has antibody against
Chlamydia pneumoniae
which is related to onset of acute myocardial infarction reduces the onset rate of acute myocardial infarction(
see
: Meier C. R. et al., JAMA, 281(5):427-431, 1999). Antibiotics such as quinolones or quinones could reduce onset rate of acute myocardial infarction, on the other hand, antibiotics of macrolide which are known to be the most effective agents to kill
Chlamydia pneumoniae
have no effect on reducing the onset rate of acute myocardial infarction, suggesting that the antibiotics are not merely killing pathogenic microorganisms. Thus, antibiotics have been regarded as thrombosis inhibitors or thrombolytic agents, however, there is no evidence of relations between antibiotics and thrombus, hence, antibiotics can be conjectured to work on acute myocardial infarction via other mechanism than involvement of thrombus. The fact that antibiotics exert a certain effect on acute myocardial infarction without involvement of thrombus implies that antibiotics may protect cells from destruction caused by inadequate supply of oxygen and glucose due to the blockage of blood vessels. Accordingly, it could be expected that the patient who has ischemia due to the blockage of blood vessel can be recovered by using antibiotics, however, there is still little progress in researches of this area.
Under the circumstances, there is a continuing need to understand the mechanism of inhibiting cell damage which is prelude to ischemia and to develop an agent effectively inhibiting the ischemic cell damage.
SUMMARY OF THE INVENTION
The present inventors have made an effort to elucidate the mechanism of inhibiting cell damage which is prelude to ischemia and to develop a therapeutic agent effectively inhibiting the said ischemic cell damage, and, based on the fact that the death of cells under hypoxic and hypoglycemic condition is progressed via apoptosis, they discovered that the addition of antibiotics of quinolones, quinones, aminoglycosides or chloramphenicol to the cells under hypoxic and hypoglycemic condition can dramatically inhibit apoptosis, furthermore, the apoptosis can be inhibited by administering the antibiotics to an individual under ischemic condition in an amount of administering to the individual infected with pathogenic microorganisms.
A primary object of the present invention is, therefore, to provide a therapeutic agent which inhibits apoptosis under ischemic condition.
REFERENCES:
patent: 5532239 (1996-07-01), Pruna
patent: 5677288 (1997-10-01), Marangos
patent: 5830784 (1998-11-01), Zhang et al.
patent: 6180612 (2001-01-01), Hockensmith et al.
patent: 6277393 (2001-08-01), Yrjanheikki et al.
patent: 6281199 (2001-08-01), Gupta
patent: WO 90/00061 (1990-01-01), None
patent: WO 92/22819 (1992-12-01), None
Saikku, P., et al. (1988)Serological Evidence of an Association of a Novel Chlamydia, Twar, with Chronic Coronary Heart Disease and Acute Myocardial Infarction. Lancet, 2(8618) pp. 983-985.
Gupta, S., et al. (1997)Elevated Chlamydia Peneumoniae Antibodies, Cardiovascular Events, and Azithromycin in Male Survivors of Myocardial Infarction. Circulation, 98(2) pp. 404-407.
Muhlestein, JB, et al. (2000)Radomized Secondary Prevention Trial of Azithromycin in Patients with Coronary Artery Disease: Primary Clinical Results of the ACADEMIC Study. Circulation, 102(15) pp. 1755-1760.
Gurfinkel, E., et al. (1997)Randomised Trial of Roxithromycin in Non-Q-Wave Coronary Syndromas: ROXIS Pilot Study. Lancet, 350(9075) pp. 404-407.
Sinisalo, J., et al. (2002)Effect of 3 Months of Antimicrobial Treatment with Clarithromycin in Acute Non-Q-Wave Coronary Syndrome. Circulation, 105(13) pp. 1555-1560.
Folsom, AR. (1999)Antibiotics for Prevention of Myrocardial Infarction? Not Yet!JAMA, 281(5) 461-462.
Meier, CR, et al. (1999)Antibiotics and Risk of Subsequent First-time Acute Myrocardial Infarction. JAMA, 281(5) pp. 427-431.
Haider, AW, et al. (1999)Letters, Jama 282(21) 1997-2001.
Hammerschlag, MR. (1994)Antimicrobial Susceptibility and Therapy of Infections Caused by Chlamydia Pneumoniae, Antimicrob. Agents Chemother. 38(9) pp. 1873-1878.
Jackson, LA, et al. (1999)Lack of Association between First Myrocardial Infarction and Past Use of Erythromycin, Tetracycline, or Doxycycline. Emerg. Infect. Disc., 5(2) pp. 281-284.
Luchsinger, JA, et al. (2002)Relation of Antibiotic Use to Risk of Myrocardial Infarction in the General Population. Am. J. Cardiol. 89(1) pp. 18-21.
Clark, WM, et al. (1994)Reduction of Central Nervous System Reperfusion Injury in Rabbits Using Doxycycline Treatment. Stroke 25(7) pp. 1411-1415.
Smith, JR., et al. (1994)Doxycycline Suppression of Ischemia-Reperfusion-Induced Hepatic Injury. Inflammation 18(2) pp. 193-201.
Smith, JR., et al. (1995)Protective Effects of Doxycycline in Mesenteric Ischemia and Reperfusion. Res. Commun. Mol. Pathol. Pharmacol. 88(3) pp. 303-315.
Yrjanheikki, J., et al. (1998)Tetracyclines Inhibit Microglial Activation and Are Neuroprotective in Global Brain Ischemia. Proc. Natl. Acad. Sci. USA 95(26) pp. 15769-15774.
Yrjanheikki, J., et al. (1999)A Tetracycline Derivative, Minocycline, Reduces Inflammation and protects Against Focal Cerebral Ischemia With a Wide Therapeutic Window. Proc. Natl. Acad. Sci. USA 96(23) pp. 13496-13500.
Chen, M., et al. (2000)Minocycline Inhibits Caspase-1 and Caspase-3 Expression and Delays Mortality in a Transgenic Mouse Model of Huntington Disease. Nat. Med., 6(7) 797-801.
Zhu, S., et al. (2002)Minocycline Inhibits Cytochrome c Release and Delays Progression of Amyotrophic Lateral Sclerosis in Mice. Nature 417(6884) pp. 74-78.
He, H., et al. (2001)Phosphorylation of Mitochondrial Elongation Factor Tu in Ischemic Myocardium: Basis for Chloramphenicol-Mediated Cardioprotection. Circ. Res., 89(5) pp. 461-467.
International Search Report in Application PCT/KR01/00050 completed May 30, 2001.
Kim Kyu-Won
Lee Jong-Kyun
Lee Jong-won
Lee Sang Jong
Henley III Raymond
Hypoxi Co., Ltd.
Knobbe Martens Olson & Bear LLP
LandOfFree
Therapeutic agent for ischemia which inhibits apoptosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for ischemia which inhibits apoptosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for ischemia which inhibits apoptosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3252312